Weight-Loss Drugs Prevent Heart Damage

The journey of GLP-1 agonists, the class of drugs that includes Ozempic and Wegovy, began with an unexpected source: the venom of the Gila monster. Researchers discovered that a hormone in the venom, exendin-4, was a long-acting version of the human gut hormone GLP-1, which is involved in insulin secretion and appetite regulation. This led to the development of the first GLP-1 drug, exenatide (Byetta), approved for type 2 diabetes in 2005. Initially developed for managing blood sugar, the cardiovascular benefits of these drugs soon became apparent. Landmark trials like the LEADER and SUSTAIN-6 studies showed that liraglutide and semaglutide could significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes. This shifted the perception of these medications from just glucose-lowering agents to therapies that could modify the course of cardiovascular disease. The heart-protective effects of semaglutide are not solely due to weight loss. Research indicates that these drugs also work by reducing inflammation, improving the function of blood vessel linings, and having a modest blood pressure-lowering effect. These mechanisms help to stabilize plaque in the arteries, reducing the likelihood of a rupture that could lead to a heart attack. The SELECT trial was a pivotal study that focused on individuals with pre-existing cardiovascular disease who were overweight or obese but did not have diabetes. The results demonstrated a 20% reduction in major adverse cardiovascular events, leading to an expanded FDA approval for Wegovy in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in this population. The cost of these medications is a significant consideration. Analyses have shown that while lifetime treatment could prevent hundreds of thousands of cardiovascular events, the drug costs are substantial. However, with rebates and at certain price points, semaglutide is considered cost-effective for preventing cardiovascular events. The success of GLP-1 agonists has spurred further research into their therapeutic potential beyond diabetes and weight loss. Ongoing studies are exploring their effects on conditions like chronic kidney disease, liver disease, and even neurodegenerative diseases. This growing body of evidence is solidifying the role of GLP-1 based therapies as a cornerstone in cardiometabolic medicine.